TP53 and acute myeloid leukemia: Mutant p53 proteins can potentially contribute to MDS/AML pathophysiology and progression through different molecular mechanisms: protein inactivation and loss of function in the case of biallelic hits; a dominant-negative effect of the mutant over germline wild-type p53; or finally a gain-of-function effect of the mutant protein.